News Quantified

MIST – milestone pharmaceuticals inc. - common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense [Seeking Alpha]

Milestone announces acceptance of MAA by EMA for etripamil nasal spray [Yahoo! Finance]

Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Wall

0.0%

BEAT

0.7%

MISS

-0.8%

MISS

Wells Fargo & Company

Form 8-K Milestone Pharmaceutical For: Jan 12

Form 4 Milestone Pharmaceutical For: Jan 07 Filed by: Oliveto Joseph

Form 144 Milestone Pharmaceutical Filed by: Oliveto Joseph

Form 144 Milestone Pharmaceutical Filed by: Oliveto Joseph

Form 8-K Milestone Pharmaceutical For: Jan 06

Top News Gainers

4/3 Form SC 13G/A Milestone Pharmaceutical Filed by: Venrock Healthcare Capital Partners II, L.P. 19.2%

5/9 Form 4 Milestone Pharmaceutical For: May 09 Filed by: RTW INVESTMENTS, LP 17.1%

3/6 Q4/2019 12/31/2019 EPS -0.750 ZacksConsensus -0.520 ActVsEst (0.230) - Miss 11.6%

1/2 Form 4 Milestone Pharmaceutical For: Dec 30 Filed by: WONG RODERICK 10.4%

3/24 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. 8.3%

5/24 Form 8-K Milestone Pharmaceutical For: May 24 7.8%

7/8 Milestone Pharmaceuticals: Interesting, But Not Well-Differentiated From Generic Competition [Seeking Alpha] 7.8%

2/5 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $26.50 price target on the stock. 5.9%

5/21 Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting 5.7%

1/13 Form 4 Milestone Pharmaceutical For: Jan 13 Filed by: RTW INVESTMENTS, LP 5.6%

Top News Decliners

3/23 Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment -87.1%

3/12 Form SC 13D/A Milestone Pharmaceutical Filed by: Novo Holdings A/S -8.4%

3/19 Form 4 Milestone Pharmaceutical For: Mar 02 Filed by: RTW INVESTMENTS, LP -7.3%

6/7 Milestone Pharmaceuticals (MIST) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow [Seeking Alpha] -6.1%

11/8 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.9%

5/15 Form 8-K Milestone Pharmaceutical For: May 13 -3.9%

3/6 Form S-8 Milestone Pharmaceutical -3.8%

6/3 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is now covered by analysts at Cowen Inc. They set a "buy" rating and a $32.00 price target on the stock. -3.3%

11/14 Milestone Pharmaceuticals to Present at Upcoming Investor Conferences -2.9%

10/3 Form 4 Milestone Pharmaceutical For: Oct 01 Filed by: RTW INVESTMENTS, LP -2.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day